Advocacy Continues on Behalf of 340B Hospitals

Posted on October 02, 2020

The 340B Drug Pricing Program is important for many MHA members and their financial health. As recently reported, advocacy efforts to protect the program are taking place.

The MHA recently sent a letter to the Michigan congressional delegation on behalf of the state’s 340B hospitals. The letter shares hospitals’ concern regarding drug manufacturers’ attempts to limit payment to contract pharmacies and other actions that are a significant detriment to 340B hospitals and the services they can provide to eligible patients because of the program. Recently, Astra Zeneca and Eli Lilly have notified covered entities of policy changes that are in direct violation of either the Health Resources and Services Administration guidance and/or the various 340B entity contracts.

Signing the letter were representatives from 68 of the more than 80 Michigan 340B hospitals. The MHA will continue to communicate with to both the Michigan delegation and to the U.S. Department of Health and Human Services on the 340B program and proposed rule changes. Members with questions may contact Laura Appel at the MHA.



Tags: Laura Appel, 340B

Posted in: Member News

MHA Updates Delivered to You

Subscribe to the MHA Monday Report weekly newsletter or our podcast, the MiCare Champion Cast, to keep informed about the latest healthcare news and events in Michigan.

MHA Monday Report
Contact us to subscribe

MiCare Champion Cast
iTunes | SoundCloud


Media Inquiries

Contact the MHA at
(517) 703-8601

Read the MHA policy on publication via MHA media.

MHA 100 Year Anniversary

Watch the video »